Cinctive Capital Management LP Has $4.61 Million Stake in STERIS plc $STE

Cinctive Capital Management LP lowered its position in STERIS plc (NYSE:STE) by 12.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,615 shares of the medical equipment provider’s stock after selling 2,741 shares during the period. Cinctive Capital Management LP’s holdings in STERIS were worth $4,606,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. raised its position in STERIS by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 12,213,521 shares of the medical equipment provider’s stock valued at $3,022,114,000 after purchasing an additional 50,393 shares during the last quarter. State Street Corp raised its holdings in shares of STERIS by 2.4% in the second quarter. State Street Corp now owns 4,188,103 shares of the medical equipment provider’s stock valued at $1,006,069,000 after buying an additional 98,220 shares during the last quarter. Orbis Allan Gray Ltd lifted its position in STERIS by 36.0% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock worth $504,486,000 after buying an additional 556,088 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in STERIS by 16.4% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,567,238 shares of the medical equipment provider’s stock worth $387,797,000 after buying an additional 221,199 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in STERIS by 4.9% during the 3rd quarter. Invesco Ltd. now owns 1,280,142 shares of the medical equipment provider’s stock worth $316,758,000 after acquiring an additional 59,443 shares during the last quarter. 94.69% of the stock is owned by institutional investors and hedge funds.

STERIS Price Performance

Shares of STE opened at $214.66 on Monday. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26. STERIS plc has a 1 year low of $204.90 and a 1 year high of $269.44. The stock has a market cap of $21.05 billion, a P/E ratio of 29.94 and a beta of 1.05. The stock’s 50-day moving average price is $250.96 and its two-hundred day moving average price is $250.52.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, hitting the consensus estimate of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.STERIS’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same quarter last year, the company posted $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, equities analysts predict that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend is Tuesday, February 17th. STERIS’s dividend payout ratio is presently 35.15%.

Insider Buying and Selling

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total value of $734,876.58. Following the sale, the director directly owned 705 shares in the company, valued at approximately $167,233.05. This trade represents a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 1.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Six equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $275.20.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.